NCT03684811 - A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

May 24, 2021

Study Completion Date

June 13, 2022

Conditions

Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)Cohort 3a and 3b: ChondrosarcomaCohort 4a and 4b: Intrahepatic CholangiocarcinomaCohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations

Interventions

DRUG

FT-2102

FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.

DRUG

Azacitidine

Azacitidine will be administered per the site's standard of care.

BIOLOGICAL

Nivolumab

Nivolumab will be administered per the site's standard of care.

DRUG

Gemcitabine and Cisplatin

Gemcitabine and cisplatin will be administered per the site's standard of care.

Trial Locations (26)

3084

Austin Hospital, Heidelberg

10032

Columbia University Medical Center, New York

13385

Hospital de la Timone, Marseille

33076

Centre de Lutte Contre Cancer (CLCC) - Institute Bergonie, Bordeaux

33136

University of Miami, Sylvester Comprehensive Cancer Center, Miami

48202

Henry Ford Hospital, Detroit

52242

University of Iowa, Holden Comprehensive Cancer Institute, Iowa City

53226

Medical College of Wisconsin, Froedtert Hospital, Milwaukee

60611

Northwestern University, Lurie Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

76508

Baylor Scott and White Medical Center, Temple

80045

University of Colorado Anschutz Medical Campus, Aurora

84112

University of Utah, Huntsman Cancer Hospital, Salt Lake City

85234

Banner MD Anderson, Gilbert

94800

Institut Gustave Roussy Cancer Campus, Villejuif

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

08901

Rutgers Cancer Institute of New Jersey, New Brunswick

VIC 3000

Peter MacCallum Cancer Centre, Melbourne

Unknown

Centre de Lutte Cancre (CLCC) - Lyon, Lyon

03080

Seoul National University Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

08035

Vall D'Hebron University Hospital, Barcelona

G12 OYN

Cancer Research Beatson Institute, Glasgow

SW3 6JJ

The Royal Marsden Hospital, London